Clicky

mobile btn
Monday, December 23rd, 2024

Biological

Oversight Subcommittee examines bioresearch labs security

The House Subcommittee on Oversight and Investigations held a hearing on Wednesday regarding strengthening oversight of high-containment laboratories. “Sweeping improvements and policy changes only work if the policies are effective,” Subcommittee Chairman Rep. Tim Murphy (R-PA) said.... Read More »

Zilinskas: U.S. biodefense needs improvement

The United States is increasingly turning to biodefense as threats against the homeland continue to grow, but the Middlebury Institute of International Studies at Monterey's Dr. Raymond Zilinskas recently warned that the larger problem remains that no one knows the true state of American... Read More »

FDA announces availability of new Zika screening test

The U.S. Food and Drug Administration announced on Wednesday that a new investigational test to screen blood donations for Zika virus is now available in areas with known mosquito-borne transmission of Zika. “The availability of an investigational test to screen donated blood for Zika virus is... Read More »

Upton, Murphy press HHS on Zika virus response

House Energy and Commerce Committee Chairman Fred Upton (R-MI), along with Oversight and Investigations Subcommittee Chairman Tim Murphy (R-PA), recently sent a letter to the U.S. Department of Health and Human Services (HHS) criticizing the department’s response to the ongoing spread of the Zika... Read More »

Interpol holds bioterrorism workshop

The International Criminal Police Organization (Interpol) held a workshop on Friday in Lyon, France, to enhance the capacity of authorities in Iraq to better prevent, detect and respond to biological threats. “I am confident this workshop will deepen our levels of awareness – not just on... Read More »

Frech: U.S. should focus on biodefense, preparation

The Blue Ribbon Study Panel on Biodefense’s “National Blueprint for Biodefense” warned that “the United States is underprepared for biological threats,” adding that “biological events may be inevitable, (but) their level of impact on our country is not.” To combat a biological... Read More »

FDA approves new anthrax treatment

The U.S. Food and Drug Administration (FDA) on Friday approved the Anthim injection to treat inhalation anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalation anthrax when alternative therapies are not available or appropriate. “As... Read More »

NIAID exercises option for RiVax

Soligenix, Inc., announced on Wednesday that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to accelerate the regulatory activities with the U.S. Food and Drug Administration (FDA) for Soligenix's heat stable ricin toxin vaccine RiVax. The NIAID’s... Read More »

WHO commends Sierra Leone’s Ebola response

The World Health Organization announced on Thursday that 42 days have passed since the last person confirmed to have Ebola virus disease in Sierra Leone tested negative for a second time. “Today marks another milestone in the country’s effort to defeat Ebola,” the WHO said. “WHO... Read More »

Uruguay sees spike in dengue fever

The National International Health Regulations (IHR) Focal Point of Uruguay announced last week that the country has seen a sustained increase in the number of suspected cases - 570 - and confirmed cases - 17 - of dengue fever. All confirmed cases were positive for dengue virus by reverse... Read More »

New study brings MERS vaccine strategy into question

A new study published this week in the online open-access journal mBio suggests that the Middle East Respiratory Syndrome coronavirus (MERS-CoV) develops mutations that make the virus less virulent, rather than more virulent. The virus causes severe respiratory infection and has a worldwide... Read More »

Ebola countermeasure has successful human trial

The Defense Threat Reduction Agency’s Joint Science and Technology Office, along with the U.S. Army Medical Research Institute of Infectious Diseases, announced this week that a compound demonstrated no adverse effects in its Phase 1 trials against the Ebola virus. The compound, GS-5734,... Read More »